Metral

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metral

Property Description
Active Ingredient Metronidazole
Pharmacological Class Nitroimidazole Antimicrobial Agent
Origin / Type Synthetic Prodrug
Forms Tablet, IV Solution, Topical Gel, Suppository
General Purpose To eliminate anaerobic bacteria and specific protozoa

What is Metral and What is its Composition?

Metral is a pharmaceutical product containing the single active substance Metronidazole, a synthetic nitroimidazole derivative requiring a medical prescription. The core chemical entity, Metronidazole (INN), functions as a prodrug that must be activated within the target microorganisms, a property critical for controlling infections caused by susceptible organisms. The composition consists of the active ingredient integrated with necessary excipients, varying by dosage form—from solid excipients for oral tablets to hydrophilic bases for topical gel preparations. Metral is differentiated by its availability in multiple forms, including its use as an established systemic treatment administered via the intravenous solution.

Metral's Pharmacological Class and Dual Action

Metral is classified as a Nitroimidazole Antimicrobial Agent, distinguished by its dual functionality against both specific bacteria and certain parasites. This classification enables it to act as both an Antibiotic and an Antiprotozoal drug. Metronidazole is recognized as an essential medicine due to its clinical role against these specific classes of pathogens. This reinforces the drug’s application in targeting obligate anaerobic bacteria and several types of protozoa. Metral is produced in various dosage forms, including the tablet and intravenous solution for systemic use, as well as forms like vaginal gel for targeted local administration.

How Does Metral Generally Work?

The fundamental principle is selective toxicity, whereby the Metronidazole prodrug is activated only within the low-oxygen environments of susceptible microorganisms. This reductive activation causes DNA strand breakage within the pathogen's cell, resulting in a bactericidal and antiprotozoal effect. This mechanism achieves the general purpose of halting the growth and eliminating the susceptible infectious organisms.

Regulatory References

  1. NIH MedlinePlus Drug Information

What side effects are possible with Metral?

Possible Side Effects and Safety Information

The safety profile of Metral (Metronidazole) is officially categorized by regulatory bodies such as the FDA and EMA based on frequency and affected body systems. These classifications guide the understanding of the medicine's risk profile, focusing on documented adverse reactions and specific constraints.

Adverse Reaction Classification

Side effects are primarily grouped by frequency and the System-Organ Class (SOC) they affect. Common reactions often involve Gastrointestinal Disorders, including nausea, vomiting, diarrhea, abdominal cramping, constipation, and a distinct metallic taste. Nervous System Disorders are also commonly reported, such as headache and anorexia. Reactions classified as Very Rare include blood cell changes (e.g., neutropenia, agranulocytosis) and hepatobiliary issues.

Serious Adverse Reactions and Duration Patterns

The official prescribing information documents serious reactions, including Encephalopathy and convulsive seizures affecting the central nervous system, and Acute Hepatic Failure. The risk of Peripheral Neuropathy (primarily sensory) is associated with prolonged or repeated courses of treatment, an important duration-related safety pattern noted in regulatory labels.

Safety Restrictions and Special Populations

Specific constraints apply to Metral. Use is restricted due to findings of carcinogenicity in animal studies, and the consumption of alcohol during treatment is documented to cause a severe disulfiram-like reaction. Systemic use is contraindicated in patients with Cockayne Syndrome due to the reported risk of severe hepatotoxicity and hepatic failure. Patients with severe hepatic impairment also require careful observation for adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information summarizes the officially documented overdose profile for Metral as detailed in government regulatory labeling (e.g., FDA, EMA). It does not constitute clinical advice.

Documented Overdose Manifestations

Classification Clinical Observations (Documented in Labeling)
Symptom Clusters Presentations typically reflect an exaggerated or severe extension of the pharmacological effects. Manifestations may include severe gastrointestinal, neurological, and significant cardiovascular signs.
Severe Outcomes Life-threatening complications, such as cardiac arrhythmia, profound hypotension leading to circulatory collapse, or severe organ toxicity, are listed as potential sequelae.

Emergency Actions and Required Medical Attention

Regulatory documents explicitly state the requirement to seek immediate medical attention upon recognition or suspicion of an overdose.

  • Required Action: Immediately cease Metral administration.
  • Emergency Contact: Contact emergency medical services or a designated Poison Control Centre without delay.

Management is primarily symptomatic and supportive. The labeling specifies whether a known, specific antidote exists for Metral and details the official, authorized supportive measures, such as monitoring requirements and interventions like administration of activated charcoal or specific life support.

Population-Specific Considerations

Official labeling may document specific risks or altered severity in vulnerable populations, such as pediatric patients or individuals with pre-existing renal or hepatic impairment.

Therapeutic Uses of Metral

Metral Quick Facts: Therapeutic Areas

  • Assists in the management of inflammation
  • Supports the treatment of specific allergic reactions
  • Contributes to the care of certain arthritic conditions
  • Used for disorders affecting the skin, blood, and eyes

Metral is a prescription medication utilized in therapeutic regimens for various conditions where a corticosteroid is indicated. Its primary role is to facilitate a reduction in inflammation, which can manifest as swelling, heat, redness, and discomfort, across multiple organ systems.

This medication is a component of treatment plans for specific forms of arthritis and a range of other conditions, including certain skin disorders and blood disorders. It may also be used in the management of particular intestinal disorders and kidney conditions, such as colitis, as part of a healthcare provider’s comprehensive approach. Additionally, Metral is applied in the care of severe, self-limiting allergic reactions and to provide relief of symptoms associated with certain forms of asthma. In specific contexts, it is included in protocols for managing certain types of cancer.

All indications and corresponding benefits are determined by a qualified healthcare professional and align with the approved therapeutic overview for corticosteroids.

Eligibility and Restrictions for Use

Who Can and Cannot Use Metral (Metronidazole) — Eligibility Profile

The eligibility profile for Metral (Metronidazole) is determined by specific contraindications and patient characteristics documented in official regulatory labeling. Use is strictly prohibited for patients with a known history of hypersensitivity to metronidazole or other nitroimidazole medicines, and for patients diagnosed with Cockayne Syndrome due to the risk of severe hepatotoxicity. Furthermore, Metral is contraindicated for patients who have taken the drug disulfiram within the last two weeks.

Eligibility Limitations and Restrictions

Population Group Regulatory Status and Limitation
Severe Hepatic Impairment Requires a mandatory dose reduction (e.g., 50%) and close monitoring.
Pregnancy Avoided or contraindicated in the first trimester unless considered essential.
Breastfeeding Not recommended; use requires the mother to interrupt breastfeeding for an extended period (e.g., 48 hours).
Pediatric Patients Safety and efficacy are not established for all indications, though some uses are approved.

These constraints define the regulatory limits on Metral use, emphasizing that eligibility is conditional upon the absence of absolute contraindications and the necessity of conditional use for specific patient groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Metral (Metronidazole) is structured around strict prohibitions and required pharmacokinetic monitoring, as outlined in regulatory documentation. Co-administration with Disulfiram is contraindicated and must be separated by a 14-day washout period due to the risk of psychotic reactions. The consumption of Alcohol and products containing Propylene Glycol is also strictly contraindicated during therapy and for at least 3 days following treatment cessation, due to the potential for a disulfiram-like reaction.

Documented Pharmacokinetic and Potentiation Effects

Metral officially potentiates the anticoagulant effect of Warfarin and other coumarins, which results in a documented prolongation of prothrombin time (INR). The drug increases the plasma concentration (AUC) of Busulfan and reduces the clearance of 5-Fluorouracil, which increases the risk of toxicity for those co-administered agents. Metral elevates serum levels of both Lithium and Ciclosporin, necessitating strict monitoring when co-administered.

Metral is subject to enzyme-mediated interactions: CYP inducers (e.g., Phenytoin) reduce its plasma levels, while CYP inhibitors (e.g., Cimetidine) officially prolong its half-life. Furthermore, the risk of QT prolongation is increased when co-administered with other agents known to prolong the QT interval.

Population-specific notes indicate that severe hepatic impairment leads to significant drug accumulation, and End-Stage Renal Disease results in the accumulation of Metral's metabolites.

Mechanism of Action

Metronidazole is initially an inert prodrug that becomes active only within the unique low-oxygen environments of susceptible bacteria and protozoa. This activation requires the drug to accept electrons from microbial enzymes like Ferredoxin, a process that converts the molecule into a highly reactive, cytotoxic intermediate. This requirement for reduction ensures a mechanism of selective toxicity, confining the cytotoxic process to the targeted pathogens. The activated intermediate rapidly engages in a lethal mechanistic cascade by forming covalent bonds with the pathogen's DNA. This irreversible molecular damage causes fragmentation and destabilization of the genetic material, immediately halting replication and all cell repair functions. This decisive bactericidal and antiprotozoal effect leads to irreversible cell damage that results in the death of the susceptible pathogen population, which is the resulting physiological change.

Dosage and Administration Information

Metral (Metronidazole) is administered according to precise instructions covering its various formulations and routes. Administration occurs via oral tablets or suspension, intravenous (IV) infusion for systemic treatment, and topical/vaginal forms for localized use, corresponding to solutions, gels, and suppositories. These distinct routes structure the entire course of therapy.

Official Dosing and Frequency

The standard dosing regimen for many systemic bacterial infections is defined by a weight-based dose of 7.5 mg/kg, administered at regular intervals, typically every six hours. The total quantity of Metral administered is restricted, specifying that the daily dose should not exceed 4 grams over a 24-hour period. Other established patterns include a single oral dose of 2 grams or a 750 mg three times daily regimen for specific parasitic infections. The duration of use is fixed and varies by indication, ranging from single-day courses to extended courses of 7 to 10 days.

Administration Conditions and Adjustments

Administration for the IV solution is procedural, requiring the dose to be infused over a period of 30 to 60 minutes. Specific adjustments are required for certain populations; for instance, a 50% dose reduction is specified for patients with severe liver dysfunction. Pediatric doses are calculated based on body weight, often in the range of 35 to 50 mg/kg/24 hours. For single-dose treatments, administration may be conducted under supervision to ensure compliance with the protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Metral

Evidence for Use in Mitral Regurgitation (MR)

Metral was evaluated in research exploring the use of Metral in patients with Mitral Regurgitation ( MR), a condition characterized by fluctuating or episodic heart-related symptoms. The research primarily took the form of clinical trials exploring short-term symptom changes. These studies examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Findings indicate that in the observed populations, Metral was evaluated in studies examining patient-reported outcomes describing perceived discomfort. However, the data are still emerging, and findings were mixed regarding how consistently these patterns were observed in some studies. What remains uncertain is the long-term outcomes on the progression of MR. The follow-up durations were limited, meaning the data available on sustained changes are insufficient.


Evidence for Use in Mitral Valve Prolapse (MVP)

Research has also explored Metral in the context of Mitral Valve Prolapse ( MVP), focusing on patients experiencing periods of heightened symptoms such as chest discomfort. This research was evaluated in observational settings examining patterns related to outcomes describing episodic or acute changes. Data from studies indicate patterns related to how patients experienced outcomes capturing phases of heightened symptom activity. However, the evidence is limited, and certainty remains low because the sample sizes were modest. Research is ongoing to address uncertainties about long-term outcomes beyond symptom reporting.


Long-Term Studies and Follow-Up

The question of how Metral affects patients over extended periods was evaluated in a few specific studies. The studies monitored how outcomes related to physical discomfort changed over time in the observed populations. However, long-term effects are not fully established. Research describes some cases where the patterns were sustained, while in others, the patterns observed appeared to lessen over time. This makes it a key area where further research is ongoing.


What is Still Uncertain About Metral

A significant gap is the lack of direct comparison research— comparative evidence is lacking—making it difficult to fully contextualize how patients reported their experience. Furthermore, the data are often focused on short-term symptom changes, and the long-term effects are not fully established. Finally, the findings were mixed across various studies, especially when research examined different patient subgroups.

Key Studies & References The Metral Post-Marketing Observational Study: Patterns of Symptom Fluctuation in Mitral Valve Prolapse

Frequently Asked Questions (FAQ)

Common questions about Metral (FAQ)


Q: How quickly is Metral expected to start working?

Metral is classified as a prodrug, meaning it must be activated inside the targeted microorganisms before it can begin working. Official studies and regulatory science indicate that the drug's antimicrobial effect may begin within a few hours following administration. Clinical improvement of symptoms may require a longer duration of time.


Q: How long does the effect of Metral usually last?

Official information notes that Metral has a relatively long half-life, which means its concentration in the body persists over time. The prescribed dosing schedule is intended to maintain continuous drug levels throughout the treatment course.


Q: Is Metral safe to use during pregnancy, according to official documents?

According to official prescribing information, Metral use is advised to be avoided or is contraindicated during the first trimester of pregnancy unless a healthcare provider considers it essential. For the second and third trimesters, the decision should be made based on a benefit-risk assessment by a healthcare professional.


Q: What is the safety classification of Metral for breastfeeding?

Regulatory documents state that Metral appears in breast milk. Official guidance advises that the mother should interrupt feeding for an extended period, often noted as 48 hours, following the last dose.


Q: Can Metral cause weight gain or weight loss?

Reported adverse reactions often include loss of appetite, also known as anorexia, which may be associated with weight loss. Regulatory summaries of side effects do not list weight gain as a reported reaction.


Q: Does Metral interact with common over-the-counter pain relievers?

Official prescribing information focuses on major and moderate interactions with prescription drugs. Regulatory documents do not specifically list common over-the-counter pain relievers, such as acetaminophen or NSAIDs, as interacting agents.


Q: Does Metral have any known interactions with herbal supplements?

There are generally no interactions with specific herbal remedies documented in the official regulatory sources. However, the major restriction involves alcohol and propylene glycol. It is important to check all liquid supplements for the presence of these restricted ingredients.


Q: What is known about Metral’s effect on sleep patterns?

As a medicine that affects the nervous system, regulatory documents list insomnia, or trouble sleeping, as a possible adverse reaction. This is categorized under nervous system disorders that patients have reported during treatment.


Q: What is the official recommended time of day to take Metral?

The schedule for administration is typically determined by the prescribed interval to maintain consistent blood levels. For most standard oral forms, Metral can be taken either with or without food. However, official instructions for extended-release tablets specify that they must be taken on an empty stomach.


Q: Is Metral officially recommended to be taken with food?

While most oral formulations of Metral can be taken with or without food, taking the medicine with food is generally recommended. This may help to mitigate the risk of gastrointestinal side effects, such as nausea or stomach upset.


Q: Why do some people experience initial side effects with Metral that later go away?

Patient information leaflets often describe that certain side effects, particularly common issues like nausea, metallic taste, or headache, may be temporary. These effects tend to lessen or go away as the patient's body adjusts to the medicine or once the short course of treatment is finished.


Q: Is Metral considered a narcotic or controlled substance?

Metral (metronidazole) is classified by regulatory bodies as a Nitroimidazole Antimicrobial Agent, which is a type of antibiotic and antiprotozoal drug. It is not listed or regulated as a narcotic or a controlled substance.


Q: Can Metral be used by children?

Metral is approved for use in pediatric patients for a limited number of specific indications and age groups. Official information notes that the dosage must be calculated based on the child's body weight. However, regulatory documents also state that the safety and efficacy are not established for all indications in children.


Q: What is the approved use of Metral in older adults?

Studies have not identified geriatric-specific problems that would prevent the use of Metral. However, official information notes that older patients may have an increased likelihood of experiencing unwanted effects. Dose adjustments may also be necessary due to age-related changes in liver or kidney function.


Q: Is it possible for Metral to cause tiredness or dizziness?

Regulatory documents list effects on the nervous system, which include reports of dizziness and weakness/fatigue among patients during treatment. These are classified as possible nervous system disorders.


Q: What official warnings exist about drinking alcohol while taking Metral?

Official warnings state that alcohol and any products containing propylene glycol must be avoided while taking Metral and for at least 3 days after the final dose. This is due to the potential for a severe reaction known as a disulfiram-like effect, which can cause flushing, nausea, and rapid heartbeat.


Q: Is Metral a type of antidepressant?

Metral is formally classified by regulatory bodies as a Nitroimidazole Antimicrobial Agent. This means its function is to eliminate specific types of anaerobic bacteria and protozoa; it is not classified as a medicine used to treat depression.


Q: Can Metral affect blood pressure?

Metral is not generally listed in regulatory information as causing changes in blood pressure. However, official warnings regarding the combination of Metral and alcohol note that low blood pressure (hypotension) can be a symptom of the severe disulfiram-like reaction.


Q: Are there any specific organs that Metral is known to affect?

Official documents classify reported adverse reactions by the specific body system or organ affected. The documented systems include the gastrointestinal system, the nervous system, and, less commonly, the blood/lymphatic system and the liver (hepatobiliary system).


Q: What is the risk of dependence or withdrawal associated with Metral?

Regulatory classifications indicate that Metral is not considered to have a risk of physical dependence or addiction. However, the official prescribing information includes a caution regarding peripheral neuropathy (nerve damage), which is associated with prolonged or repeated courses of treatment.


Q: Does Metral cause any long-term health issues mentioned in studies?

Official warnings note that Metral has been shown to be carcinogenic in certain animal studies; however, the clinical relevance of this finding is currently uncertain. Furthermore, the risk of peripheral neuropathy, which is a form of nerve damage, is associated with prolonged or repeated courses of treatment.


Q: Is Metral affected by grapefruit or grapefruit juice?

Official prescribing information lists known interactions with other drugs and substances that may affect how Metral works. Regulatory documents do not list grapefruit or grapefruit juice as having a known or specified interaction with Metral.


Q: Are there any restrictions on diet while taking Metral?

Official restrictions are focused on liquid substances that can react with the medicine. The main restrictions are the need to strictly avoid alcohol and products containing propylene glycol during therapy and for at least three days after treatment ends. No other specific food restrictions are listed.


Q: Is Metral a short-term or long-term treatment?

Metral is described in official information as being primarily a short-term treatment. The courses of therapy are typically of a fixed duration, often ranging from a single day to an extended course of 7 to 10 days, depending on the indication.


Q: What evidence exists about Metral's effectiveness in real-world settings?

Official research summaries primarily rely on data from controlled clinical trials and observational studies. There is a documented gap in research, and comparative evidence is lacking, which makes it difficult to fully contextualize how patients report their experience outside of these structured study settings.


Q: What does 'Metral is generally well-tolerated' mean?

The phrase 'generally well-tolerated,' when used in official medical summaries, indicates that while the medicine does have documented side effects, most patients in clinical trials are able to complete the prescribed course of therapy. It suggests that the side effects experienced are usually manageable for the majority of patients.


Q: Is it true that Metral research evidence is limited for certain groups?

Regulatory summaries of research note that the findings were mixed across various studies, particularly when evidence was examined for different patient subgroups. Additionally, official information states that safety and efficacy are not established for all pediatric indications.


Q: Can Metral be split or crushed?

Extended-release tablets should not be crushed or chewed, as this can affect how the medicine is absorbed. Tablets should not be split or crushed unless the specific formulation has a score line and a healthcare professional provides explicit instructions.


Q: What should be done if an allergic reaction is suspected while taking Metral?

Official patient safety information provides guidance for serious reactions. If signs of a severe allergic reaction occur, such as swelling of the face, throat, or tongue, or if you experience trouble breathing, the medication should be discontinued and immediate medical attention should be sought.


Q: Does Metral interact with birth control pills?

Official regulatory information indicates that Metral may reduce the effectiveness of some birth control pills, specifically those containing the ingredient ethinyl estradiol. This interaction may reduce the effectiveness of the contraceptive, which could increase the risk of pregnancy.


Q: How is Metral eliminated from the body?

Metral is eliminated from the body through a two-step process: it is first metabolized (broken down) by the liver into different compounds. These compounds, both active and inactive, are then predominantly removed from the body via the kidneys and excreted in the urine.


Q: Can Metral affect mood or cause emotional changes?

Metral has been associated with effects on the nervous system. Regulatory documents list reported reactions that may include irritability, confusion, depression, and other mood or mental changes among patients.

How should Metral be stored and disposed of?

How to Store and Dispose of Metral (Metronidazole)

Official regulatory labeling dictates specific storage and disposal requirements to maintain product stability and safety.

Storage Requirements

  • Oral Formulations (Tablets/Capsules): Must be stored at Controlled Room Temperature, typically 15 C to 30 C. The container must be kept tightly closed and dispensed with a child-resistant closure.
  • Intravenous (IV) Solution: Must be stored below 30 C and protected from light. Any unused portion from a single-dose IV container must be discarded.
  • General Rule: All forms must be kept out of the reach of children and pets.

Disposal Instructions

Unused or expired Metral should be discarded via a drug take-back program (if available). If not, it can be mixed with an undesirable substance (e.g., used coffee grounds) and placed into a sealed container for household trash, per official guidelines. Medicines must not be flushed down the toilet unless explicitly instructed by the product label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metral found in:

A-Z Index: